Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Karyopharm Therapeut (KPTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 303,103
  • Shares Outstanding, K 60,864
  • Annual Sales, $ 30,340 K
  • Annual Income, $ -178,410 K
  • 60-Month Beta 3.24
  • Price/Sales 9.73
  • Price/Cash Flow N/A
  • Price/Book 1.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.84
  • Number of Estimates 8
  • High Estimate -0.59
  • Low Estimate -0.96
  • Prior Year -0.78
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.60 +5.65%
on 04/18/19
5.95 -18.32%
on 04/01/19
-0.58 (-10.66%)
since 03/22/19
3-Month
3.92 +23.98%
on 03/01/19
9.51 -48.90%
on 02/19/19
-4.15 (-46.06%)
since 01/24/19
52-Week
3.92 +23.98%
on 03/01/19
21.71 -77.61%
on 08/30/18
-8.76 (-64.32%)
since 04/24/18

Most Recent Stories

More News
Shares of Biocryst Pharm Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (BCRX , SPPI , KPTI , NVTA , NTRA )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

SPPI : 9.44 (-2.18%)
BCRX : 7.99 (-1.84%)
KPTI : 4.86 (-2.41%)
New Research Coverage Highlights BioMarin Pharmaceutical, EnLink Midstream, GCI Liberty, Vistra Energy, BioTime, and Karyopharm Therapeutics -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN),...

ENLC : 12.20 (-1.29%)
VST : 26.59 (+0.64%)
BTX : 1.25 (-0.79%)
BMRN : 85.49 (-0.59%)
KPTI : 4.86 (-2.41%)
GLIBA : 58.55 (unch)
Karyopharm Thera Set to Possibly Rebound After Yesterday's Selloff of 1.62%

Karyopharm Thera (NASDAQ:KPTI) traded in a range yesterday that spanned from a low of $5.44 to a high of $5.53. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $5.53...

KPTI : 4.86 (-2.41%)
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase...

KPTI : 4.86 (-2.41%)
Shares of Chemocentryx Inc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (CCXI , KPTI , EPZM , MYGN , VNDA )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

KPTI : 4.86 (-2.41%)
CCXI : 12.70 (-0.63%)
EPZM : 12.53 (-1.34%)
Relatively Good Performance Detected in Shares of Karyopharm Thera in the Biotechnology Industry (KPTI , VCYT , ALDR , NBIX , RDUS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

VCYT : 23.36 (-1.48%)
ALDR : 13.68 (-0.51%)
KPTI : 4.86 (-2.41%)
Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance

Veeva Systems (NYSE:VEEV) today announced that life sciences companies are adopting Veeva Nitro to accelerate their data warehouse projects and deliver faster insights to the...

VEEV : 136.65 (+0.08%)
KPTI : 4.86 (-2.41%)
MNKD : 1.53 (-4.38%)
Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict

Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.

LCI : 7.19 (-0.14%)
AITB : 4.7200 (-2.68%)
KPTI : 4.86 (-2.41%)
INFI : 1.55 (-1.27%)
Shares of KPTI Down 39.0% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Karyopharm Thera (NASDAQ:KPTI) on January 29th, 2019 at $8.41. In approximately 2 month, Karyopharm Thera has returned 39.00% as of today's recent price of $5.13.

KPTI : 4.86 (-2.41%)
Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA)...

KPTI : 4.86 (-2.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade KPTI with:

Business Summary

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.

See More

Key Turning Points

2nd Resistance Point 5.07
1st Resistance Point 4.97
Last Price 4.86
1st Support Level 4.78
2nd Support Level 4.69

See More

52-Week High 21.71
Fibonacci 61.8% 14.91
Fibonacci 50% 12.81
Fibonacci 38.2% 10.72
Last Price 4.86
52-Week Low 3.92

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar